Table 3.

Pregnancy outcomes by SLE clinical disease activity and presence of the anti-dsDNA antibody, based on measurements made at each trimester. Only women observed during the trimester of pregnancy under study were included in each group.

	Low-activity SLE		High-activity SLE		p
	Anti-dsDNA Absent (%)	Anti-dsDNA Present (%)	Anti-dsDNA Absent (%)	Anti-dsDNA Present (%)	Compares All 4 Groups	Compares Low and High Activity	Compares with/without Anti-dsDNA
First trimester
N	92	61	3	9
Fetal loss	12 (13)	10 (16)	1 (33)	4 (44)	0.46	0.049	0.29
Preterm^*	30 (38)	22 (43)	0	4 (80)	Too few^**	Too few^**	0.27
SGA^†	12 (15)	8 (16)	1 (50)	2 (40)	Too few^**	Too few^**	0.77
Second trimester
N	131	63	13	16
Fetal loss	6 (5)	8 (13)	3 (23)	3 (19)	0.11	0.019	0.039
Preterm^*	39 (31)	23 (42)	7 (70)	11 (85)	0.0029	0.0003	0.032
SGA^†	25 (20)	12 (22)	2 (20)	2 (15)	0.96	0.71	0.94
Third trimester
N	121	62	21	9
Fetal loss	1 (1)	0 (0)	3 (14)	0 (0)	Too few^**	Too few^**	Too few^**
Preterm^*	40 (33)	26 (42)	11 (61)	4 (44)	0.17	0.061	0.45
SGA^†	24 (20)	15 (24)	8 (44)	0 (0)	0.18	0.36	0.69

↵* Percentages are of live births that were preterm (delivered prior to 37 weeks gestation).
↵** Too few events to allow statistical analysis.
↵† Small for gestational age: birth weight < 10th percentile for gestational age. SLE: systemic lupus erythematosus.